Biotech

Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin

SAN FRANCISCO, CA and SAN RAFAEL, CA: Talazoparib Is a Highly-Potent PARP Inhibitor in Phase 3 Development for the Treatment of BRCA-Mutated Breast Cancer; Clinical Activity Observed in Multiple Oncology Opportunities With Potential for M ...

Nerium Biotechnology Files Claim to Enforce Contractual Rights

SAN ANTONIO, TEXAS: ...

BIOflex Technologies Inc. Announces Appointment of New Directors and Management Changes

MONTREAL, QUEBEC: ...

Matthew B. Lehman Appointed Chief Executive Officer of M Pharmaceutical, Inc.

VANCOUVER, BRITISH COLUMBIA: ...

Corbus Pharmaceuticals'' Investigational Drug Resunab(TM) Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis

NORWOOD, MA: ...

BioMalaysia and ASEAN Bioeconomy 2015 Recognizes Sentinext Therapeutics With Bio Innovation of the Year Award

KUALA LUMPUR, MALAYSIA: ...

Global Blood Therapeutics Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

SOUTH SAN FRANCISCO, CA: ...

Microbix Revenue for First Nine Months Grows 12%

TORONTO, ONTARIO: Company Provides Update on Strategic Priorities ...

ProMetic Reports its Second Quarter 2015 Highlights and Financial Results

LAVAL, QUEBEC: - Cash position of $56.7 million at end of second quarter - Revenues for the second half of 2015 expected to exceed $20 million - Revenue of $2.9 million recognized during second quarter of 2015 - Clo ...

Boston Therapeutics, Inc. Reports Second Quarter Results and Provides Corporate Update

MANCHESTER, NH: ...